FIND A BIOALPS ACTOR
blur-business-close-up-287227

Anergis Announces Results of the ATIBAR Trial

06.09.2017
Share this article
Anergis, a company developing proprietary ultra-fast allergy immunotherapy, announced today the top-line results from the ATIBAR trial, a Phase IIb field-based clinical trial with Anergis’ lead compound AllerT for patients with birch pollen allergy.